BTI
ALNY icon

Blue Trust Inc’s Alnylam Pharmaceuticals ALNY Stock Holding History

Blue Trust Inc’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.4K Sell
224
-42
-16% -$12.7K ﹤0.01% 1216
2026
Q1 		$88K Sell
266
-18
-6% -$6.13K ﹤0.01% 1083
2025
Q4 		$113K Sell
284
-65
-19% -$28.8K ﹤0.01% 996
2025
Q3 		$159K Sell
349
-944
-73% -$384K ﹤0.01% 889
2025
Q2 		$422K Buy
1,293
+135
+12% +$37.4K 0.01% 511
2025
Q1 		$313K Buy
1,158
+293
+34% +$75.3K ﹤0.01% 553
2024
Q4 		$204K Buy
865
+403
+87% +$106K ﹤0.01% 652
2024
Q3 		$112K Buy
462
+375
+431% +$97.6K ﹤0.01% 1158
2024
Q2 		$13K Buy
87
+72
+480% +$11.4K ﹤0.01% 1833
2024
Q1 		$2.24K Sell
15
-27
-64% -$4.5K ﹤0.01% 1803
2023
Q4 		$7K Sell
42
-59
-58% -$10.1K ﹤0.01% 1692
2023
Q3 		$19K Buy
101
+10
+11% +$1.91K ﹤0.01% 1191
2023
Q2 		$18K Sell
91
-15
-14% -$2.97K ﹤0.01% 1075
2023
Q1 		$25K Sell
106
-2
-2% -$420 ﹤0.01% 1282
2022
Q4 		$21K Buy
108
+87
+414% +$18.6K ﹤0.01% 1271
2022
Q3 		$3K Buy
21
+8
+62% +$1.53K ﹤0.01% 1661
2022
Q2 		$2K Buy
+13
New +$1.84K ﹤0.01% 1625

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Blue Trust Inc's ALNY Position: Q2 2026 in Review

Blue Trust Inc reduced its Alnylam Pharmaceuticals (ALNY) stake by 16% in Q2 2026, selling an estimated $12.7K and leaving 224 shares worth $67.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1216.

Blue Trust Inc first reported a position in ALNY in Q2 2022 and has held it in 17 quarters since. The position peaked at $422K in Q2 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Blue Trust Inc held 224 shares of Alnylam Pharmaceuticals worth $67.4K as of Q2 2026.
  • Blue Trust Inc sold 42 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $12.7K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #1216 holding.
  • Blue Trust Inc first reported a position in Alnylam Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • Blue Trust Inc's Alnylam Pharmaceuticals position peaked at $422K in Q2 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.